For patients with interstitial lung disease (ILD), a subsequent diagnosis of pulmonary hypertension substantially increases utilization of healthcare resources as well as costs.
Patients with interstitial lung disease who are subsequently diagnosed with pulmonary hypertension experience a significant increase in healthcare resource utilization and costs.
Image credit: stock.adobe.com - ImageFlow
Real-world healthcare resource utilization (HCRU) and costs increase substantially for patients with interstitial lung disease (ILD) who are subsequently diagnosed with pulmonary hypertension (PH), according to research comparing patient data in the 12 months before and after a PH-ILD diagnosis. The findings were published in BMC Pulmonary Medicine.
There are more than 200 types of ILD, and many times a doctor cannot find a reason for the disease, according to the Pulmonary Fibrosis Foundation. In these cases, the most common type of idiopathic ILD is idiopathic pulmonary fibrosis (IPF). More than 250,000 Americans have ILD and pulmonary fibrosis, which is a scarring of the lungs in many types of ILD.
Scarring to the lungs in patients with ILD impacts their ability to breathe and over the long term, the disease causes respiratory and heart failure. At the initial diagnosis of IPF, PH prevalence is 8% to 15%, but this increases to 29% to 46% when patients are being evaluated for a lung transplant, and up to 86% when a transplant takes place.
“Patients with PH-ILD and progressive pulmonary fibrosis can decline rapidly and have particularly high rates of respiratory failure and death,” wrote the authors of the new study.
Currently, there are two drugs approved for IPF— nintedanib and pirfenidone—but neither of them have been studied regarding their effect on PH attributed to IPF, the authors noted. There is one FDA-approved drug for PH-ILD, Treprostinil, which is available in two inhaled forms.
The authors analyzed the Truven Health MarketScan Commercial Claims and Encounters Database and Medicare Supplemental Database between June 2015 to June 2019 in order to better understand treatment patterns, HCRU and health-related costs for patients with ILD before and after a subsequent PH diagnosis.
A total of 9,379 patients were identified has having a claim for ILD and PH, but only 122 per included after the selection criteria. The mean age was 63.7 years and 64.8% were female. Slightly more than half (54.9%) had commercial insurance, and 32.0% lived in the South. Chronic pulmonary disease (94.3%), diabetes (36.1%) and rheumatic disease (34.4%) were the most common comorbidities.
The medications used prior to the PH diagnosis mostly continued to be used after the diagnosis. The most commonly used was corticosteroids (43.4% pre-index and 53.5% post-index), calcium channel blockers (25.4% pre-index and 36.9% post-index) and oxygen (12.3% pre-index and 25.4% post-index).
Prior to PH diagnosis, 29.5% of patients experienced a hospitalization, which increased to 59.0% after the PH diagnosis. In addition, the mean number of inpatient visits, length of stay per hospitalization, hospital bed days and intensive care unit days were all significantly higher after a PH diagnosis compared with before the PH diagnosis. The mean number of outpatient visits was also significantly higher after PH diagnosis.
The authors also found that the mean number of unique prescriptions filled increased significantly from 37.5 a year prior to the PH diagnosis to 46.4 a year after.
Mean total healthcare costs increased significantly from $43,201 to $108,387 driven mostly by increased inpatient costs. Mean hospitalization costs were $13,133 prior to the PH diagnosis and increased to $63,218 after the PH diagnosis. The cost of prescriptions increased 66% from before the diagnosis ($7,913) to after ($13,153).
According to the authors, the data suggests that a subsequent PH diagnosis for patients with ILD substantially increases utilization of healthcare resources as well as costs.
Among the limitations that the authors noted were the retrospective nature of the study since the data were captured for reimbursement purposes and there may be inaccuracies in the diagnostic coding or pharmacy claims. The data may only include patients with insurance, so findings might not be generalizable to uninsured patients.
“…PH is a costly and complex disease,” the authors concluded. “However, patients with ILD appear to experience a uniquely high medical and healthcare cost burden after diagnosis of pulmonary hypertension. The timely management and treatment of PH-ILD is needed to mitigate the clinical and economic consequences of disease progression.”
Remote Care Advancement for Heart Failure, COPD and Diabetes Patients
February 24th 2021In this week's episode of Tuning In to the C-Suite podcast, MHE's Briana Contreras spoke with Dr. Rob Kowal, chief medical officer of the Cardiac Rhythm and Heart Failure division at Medtronic. The two discussed how remote monitoring and IoT is changing healthcare and how remote technology is also gaining a wide-spread adoption to monitor patients at home who have chronic conditions like heart failure, chronic obstructive pulmonary disease and diabetes.
Listen
Jack Linehan of Epstein Becker Green Discusses Drug Coupons, Accumulators
July 9th 2020In this week's episode of Tuning Into The C-Suite podcast, Senior Editor Peter Wehrwein has a conversation with John "Jack" Linehan, a lawyer for Epstein Becker Green, about coupons and accumulators. Jack is an expert on drug distribution and reimbursement, and few people know as much about coupons and accumulators as he does. Peter and Jack go over some of the basics, who is advantaged and disadvantaged, and then dive into some the details on CMS regulations and how recent proposed changes to Medicaid best price rules would, if finalized, affect coupons and accumulators.
Listen
New Study Points Out Doubling of Hospitalizations and Healthcare Costs for PH-ILD
August 5th 2024A new study conducted by researchers at the United Therapeutics Corporation in Durham, NC, looked to characterize PH-ILD disease burden by analyzing healthcare resource utilization (HCRU) and cost data.
Read More